The Trump administration’s push to bring US drug spending down is a powerful incentive for pharmaceutical companies to boost prices and reduce access elsewhere in the world, a study found.
The Trump administration’s push to bring US drug spending down is a powerful incentive for pharmaceutical companies to boost prices and reduce access elsewhere in the world, a study found.
Lire l’article complet sur le site source
Bloomberg — Markets (EN)